Abstract: Compounds of formula (I), compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

Abstract: Compounds of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Abstract: Compounds of the formula I; 1

Abstract: 1 Compounds of formula (I) wherein Z is —CH2SR and R represents hydrogen or —COCH3, are useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Abstract: A simple, non-invasive device and method for treating oropharyngeal, respiratory, and oral motor neuromuscular disorders provides electrical stimulation to various regions of a patient. The method and device offer an effective and non-invasive treatment for these disorders. The device is an electrical neuromuscular stimulator that includes a pulse generator for generating a series of electrical pulses and a processor coupled to the pulse generator for controlling its operation. An electrode array of uni-directional or bi-directional electrodes is coupled to the pulse generator and provides electrical stimulation to the appropriate neck, chest, or facial region of the patient. Using bi-directional snap electrodes, for example, the electrode array may also generate electrical feedback signals in response to the neuromuscular stimulation of the patient.

Abstract: Compounds of the formula I 1

Abstract: A simple, non-invasive device and method for treating oropharyngeal, respiratory, and oral motor neuromuscular disorders provides electrical stimulation to various regions of a patient. The method and device offer an effective and non-invasive treatment for these disorders. The device is an electrical neuromuscular stimulator that includes a pulse generator for generating a series of electrical pulses and a processor coupled to the pulse generator for controlling its operation. An electrode array of uni-directional or bi-directional electrodes is coupled to the pulse generator and provides electrical stimulation to the appropriate neck, chest, or facial region of the patient. Using bi-directional snap electrodes, for example, the electrode array may also generate electrical feedback signals in response to the neuromuscular stimulation of the patient.

Abstract: A simple, non-invasive device and method for treating oropharyngeal, respiratory, and oral motor neuromuscular disorders provides electrical stimulation to various regions of a patient. The method and device offer an effective and non-invasive treatment for these disorders. The device is an electrical neuromuscular stimulator that includes a pulse generator for generating a series of electrical pulses and a processor coupled to the pulse generator for controlling its operation. An electrode array of uni-directional or bi-directional electrodes is coupled to the pulse generator and provides electrical stimulation to the appropriate neck, chest, or facial region of the patient. Using bi-directional snap electrodes, for example, the electrode array may also generate electrical feedback signals in response to the neuromuscular stimulation of the patient.

Abstract: This invention is directed to a simple, non-invasive method and device for treating dysphagia and artificially promoting swallowing by electrical stimulus. In the present invention, a plurality of electrodes are selectively placed in electrical contact with tissue of a pharyngeal region of patient and a series of electrical pulses in electrical contact with each of the plurality of electrodes with a generator. The generator includes a pulse rate modulator for generating each of the electrical pulses having a frequency generally fixed at 80 hertz, a pulse width modulator for generating each pulse of the series of electrical pulses at a duration generally fixed at 300 microseconds, and a governor for regulating the electrical pulses such that at least one of current so as not to exceed 4.4 milliamps RMS or power so as not to exceed 9.6 MW RMS. The electrical pulses selectively stimulate muscles located proximate to the selectively placed electrodes to initiate swallowing.

Abstract: Compounds of the formula, ##STR1## and pharmaceutically-acceptable salts thereof, which are useful as antagonists of the pain-enhancing effects of E-type prostaglandins, processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating pain comprising the administration of such compounds.

Abstract: This invention is directed to a simple, non-invasive method and device for treating dysphagia and artificially promoting swallowing by electrical stimulus. In the present invention, a plurality of electrodes are selectively placed in electrical contact with tissue of a pharyngeal region of patient and a series of electrical pulses in electrical contact with each of the plurality of electrodes with a generator. The generator includes a pulse rate modulator for generating each of the electrical pulses having a frequency generally fixed at 80 hertz, a pulse width modulator for generating each pulse of the series of electrical pulses at a duration generally fixed at 300 microseconds, and a governor for regulating the electrical pulses such that at least one of current so as not to exceed 4.4 milliamps RMS or power so as not to exceed 9.6 MW RMS. The electrical pulses selectively stimulate muscles located proximate to the selectively placed electrodes to initiate swallowing.

Abstract: The invention provides compounds of formula I: ##STR1## wherein A, B, D, X, R.sup.1, and R.sup.3 have any of the values defined in the specification, as well as N-oxides thereof, S-oxides thereof, pharmaceutically acceptable salts thereof, and in vivo hydrolizable esters and amides thereof, that are useful to relieve pain. The invention also provides pharmaceutical compositions as well as synthetic and therapeutic methods relating to such compounds.

Abstract: A simple, non-invasive device and method for treating oropharyngeal disorders provides electrical stimulation to the pharyngeal region of a patient. Oropharyngeal disorders may cause an inability to swallow or difficulty in swallowing. The method and device provide an effective and non-invasive treatment for these disorders which is substantially more effective than traditional treatment methods, such as thermal stimulation. The method and device also effectively treat worst-case dysphagia (the inability to swallow) resulting from neurodegeneration and strokes. The device, an electrical pharyngeal neuromuscular stimulator, includes one or more pulse generators for generating a series of electrical pulses and a processor coupled to the pulse generators for controlling their operation. A switching network is also coupled to the pulse generators.

Abstract: The present invention relates to compounds of formula (I), ##STR1## wherein A is an optionally substituted phenyl naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, thienyl, thiazolyl, oxazolyl, thiadiazolyl having at least two adjacent ring carbon atoms or a bicyclic ring system, provided that the --CH(R.sup.3)N(R.sup.2)B--R.sup.1 and --OCH(R.sup.4 --)--D linking groups arm positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom positioned ortho to the --OCHR.sup.4 -- linking group (and therefore in the 3-position relative to the --CHR.sup.3 NR.sup.2 -- linking group) is not substituted; B is an optionally substituted ring system; D is an optionally substituted ring system; R.sup.1 is a variety of group as defined in the description; R.sup.2 is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, phenylC.sub.1-3 alkyl or 5- or 6-membered heteroarylC.sub.1-3 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 is hydrogen or C.sub.1-4 alkyl; and N-oxides of NR.

Abstract: This invention relates to substituted and unsubstituted ???(aryl- and heteroaryl-) alkyl-, alkyloxy-, alkylthio-, oxo-, thio-, and alkylamino!- heteroaryl and aryl!- alkylamino-, aminoalkyl-, alkyloxy-, and alkylthio!- aryl and heteroaryl compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, which are useful as antagonists of the pain enhancing effects of E-type prostaglandins, to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods for treating pain comprising the administration of such compounds.

Abstract: The invention relates to compounds of the formula (I): ##STR1## wherein A, B and D are various ring systems such as phenyl, R.sup.1 includes carboxy, R.sup.3 is hydrogen or C.sub.1-4 alkyl and Z is a linking group such as --(CH(R.sup.5)).sub.m -- wherein m is 2, 3 or 4, and R.sub.5 includes hydrogen and methyl; and pharmaceutically acceptable salts and in vivo hydrolysable esters or amides thereof, processes for preparing these compounds, pharmaceutical compositions comprising them, and their use in the treatment of pain.

Abstract: This invention is directed to a simple, non-invasive method and device for treating dysphagia and artificially promoting swallowing by electrical stimulus. In the present invention, a plurality of electrodes are selectively placed in electrical contact with tissue of a pharyngeal region of patient and a series of electrical pulses in electrical contact with each of the plurality of electrodes with a generator. The generator includes a pulse rate modulator for generating each of the electrical pulses having a frequency generally fixed at 80 hertz, a pulse width modulator for generating each pulse of the series of electrical pulses at a duration generally fixed at 300 microseconds, and a governor for regulating the electrical pulses such that at least one of current so as not to exceed 4.4 milliamps RMS or power so as not to exceed 9.6 MW RMS. The electrical pulses selectively stimulate muscles located proximate to the selectively placed electrodes to initiate swallowing.

Abstract: The invention relates to tricyclic heterocycles of the formula I ##STR1## wherein X is oxy, thio, sulphinyl, sulphonyl, amino, (1-4C)alkylamino or methylene;Y is carbonyl or methylene;each R.sup.1 includes hydrogen, halogeno and various other substituents;each of m and n is 1 or 2;A.sup.1, alkylene, alkenylene or alkynylene;Het is a 5 or 6 membered heteroaryl group optionally bearing particular substituents; andG is carboxy, 1H-tetrazol-5-yl or a group of the formula:--CONH--SO.sub.2 R.sup.2wherein R.sup.2 is (1-4C)alkyl, benzyl or phenyl;and pharmaceutically-acceptable salts thereof, which possess anti-hyperalgesic properties. The invention also relates to processes for the manufacture of said tricyclic heterocycles; and to novel pharmaceutical compositions containing them.

Abstract: A compound of the formula ##STR1## wherein X has the formula --CR.sup.5 .dbd.CR.sup.6 --, --C.ident.C-- or ##STR2## wherein ring A is phenyl, naphthyl or heterocyclic; wherein R.sup.1 is hydrogen, alkyl, alkanoyl or aroyl;wherein R.sup.2, R.sup.3 and R.sup.4, which may be the same or different, each is an electron withdrawing substituent or each is hydrogen or alkyl, alkoxy or dialkylamino, provided that when ring A is phenyl or naphthyl at least one of R.sup.2, R.sup.3 and R.sup.4 is an electron-withdrawing substituent;wherein R.sup.5 and R.sup.6, each is hydrogen, halogeno or alkyl; wherein R.sup.7 is alkyl or halogenoalkyl; and wherein R.sup.8 has the formula --Y--Q--R.sup.9 wherein Y is straight- or branched-chain alkylene or alkenylene; wherein Q is --O--, --S--, --SO-- or --SO.sub.2 --;and wherein R.sup.9 is alkyl of up to 6 carbon atoms which contains one or more defined substituents, processes for their manufacture and pharmaceutical compositions containing them.

Abstract: The invention relates to tricyclic heterocycles, or pharmaceutically-acceptable salts thereof, which possess anti-hyperalgesic properties. The invention also relates to processes for the manufacture of said tricyclic heterocycles; and to novel pharmaceutical compositions containing them.The invention provides a tricyclic heterocycle of the formula I ##STR1## wherein X is oxy, thio, sulphinyl, sulphonyl, amino, (1-4C)alkylamino or methylene;Y is carbonyl or methylene;each R.sup.1 includes hydrogen and halogeno;each of m and n is 1 or 2;each of A.sup.1 and A.sup.2 is a direct link, alkylene, alkenylene or alkynylene;Ar is phenylene which may optionally bear one or two substituents; and G is carboxy, 1H-tetrazol-5-yl or a group of the formula:--CONH--SO.sub.2 R.sup.2wherein R.sup.2 is (1-4C)alkyl, benzyl or phenyl;or a pharmaceutically-acceptable salt thereof.